Drug company Sandoz, the generic arm of Novartis, may not market generic versions of Allergan’s eye drop solution Lumigan before the last patent covering it expires in 2027, a district court decided on January 14.
UK law firm Potter Clarkson LLP has made changes to its team with the appointment of two senior managers.
A US judge has said Teva Pharmaceuticals did not infringe patents belonging to a rival company after seeking approval to market a generic version of the drug.
IP law firm Sterne Kessler Goldstein & Fox PLLC has announced the election of three new directors to its life sciences team.
The US Supreme Court has refused to hear the Organic Seed Growers and Trade Association’s case against Monsanto, along with two other patent cases as revealed in a document released on January 13.
On January 10, the US Supreme Court agreed to decide on so-called ambiguous patent claims in Nautilus v Biosig Instruments.
General Electric has bought three life sciences divisions from US company Thermo Fisher Scientific in a deal worth about $1.06 billion.
Biopharmaceutical company Alnylam has paid Merck $175 million for its subsidiary Sirna Therapeutics, a firm specialising in RNA interference therapeutics.
Edwards Wildman Palmer LLP has hired Edward Glynn, a former senior official at the Federal Trade Commission.
Anishiya Abrol, a life sciences IP specialist, has been promoted to counsel at law firm Hogan Lovells.